Filing Details

Accession Number:
0001209191-21-022705
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-23 19:22:06
Reporting Period:
2021-03-22
Accepted Time:
2021-03-23 19:22:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1783183 Phathom Pharmaceuticals Inc. PHAT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1690298 Terrie Curran C/O Phathom Pharmaceuticals, Inc.
100 Campus Drive, Suite 102
Florham Park NJ 07932
President And Chief Executive Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-22 11,513 $6.95 11,513 No 4 M Direct
Common Stock Disposition 2021-03-22 10,373 $43.24 1,140 No 4 S Direct
Common Stock Disposition 2021-03-22 1,140 $44.08 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-03-22 11,513 $0.00 11,513 $6.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
855,687 2029-08-28 No 4 M Direct
Footnotes
  1. Represents shares of common stock received upon exercising a stock option.
  2. All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.81. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The stock option was granted on August 29, 2019 and vested with respect to 25% of the shares of common stock on August 29, 2020, and thereafter vests in equal monthly installments over the following three years.